Are you more inclined to use neoadjuvant endocrine therapy over neoadjuvant chemotherapy or upfront surgery for your ER+HER2- breast cancer patients during the COVID19 pandemic?

For clinically low risk early stage node negative tumors that are strongly ER/PR+ HER2-, neoadjuvant endocrine therapy with follow up is reasonable during this phase of the pandemic. ASCO has released some guidance to help with these questions. Ultimately, we will need to work together to conserve m...